Through Save Legs. Change Lives.™, Janssen seeks to elevate PAD research, collaboration, education and screening for communities placed at increased risk of cardiovascular disease
The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the launch of Save Legs. Change Lives.™ Spot Peripheral Artery Disease Now, a multi-year initiative aimed at creating urgency and action to address the hidden threat of peripheral artery disease (PAD)-related amputation, with an initial focus on reaching Black Americans, who are more than twice as likely to be impacted by PAD.1 Janssen has joined forces with leading professional associations, healthcare systems and community organizations to advance equitable care for individuals and communities placed at an increased risk for cardiovascular disease in the U.S.
Cardiovascular disease – also known as heart disease – is the leading cause of death in the U.S.2 and can affect more than just the heart.3 One serious condition that often goes underdiagnosed and undertreated is PAD,4 a common circulatory condition that causes blood vessels to narrow and reduces blood flow to the limbs, most often the legs.5 PAD affects an estimated 20 million Americans,6 yet only approximately 8.5 million are diagnosed.7 If left untreated, PAD can lead to serious events including heart attack, stroke, acute limb ischemia or amputation.5
Black Americans experience disproportionate rates of cardiovascular disease,8 and – as a result of higher rates of asymptomatic PAD,9 less access to quality vascular care10 and greater risk for delays in care9 – are up to four times more likely than white Americans to have a PAD-related amputation.10
“While health inequities have long existed, the last several years have brought them to the forefront of our collective consciousness. Black Americans are placed at disproportionate risk of losing legs and lives – a reality we all must actively address,” said Dr. Pernessa Seele*, Founder and CEO, The Balm in Gilead, Inc., a faith-based organization engaged in eliminating health disparities. “We believe the most effective way to eliminate the alarming health disparities within Black populations is for intentional, sustained and compassionate action by the healthcare industry, public health and faith communities.”
PAD is a leading cause of amputations in the U.S.,10 with rates continuing to rise.11 Amputations are a devastating complication of PAD and are associated with high mortality, despite being largely preventable.10 Tragically, PAD-related amputations are directly correlated to an increased risk of death, with 70 percent of patients with PAD who have a leg amputation dying within three years.12
Save Legs. Change Lives.™ has three main areas of focus: driving research, collaborating with powerful partners, and empowering individuals and communities.
Research to Break Down Barriers to PAD Screening and Increase Equitable Care
As part of the initiative, Janssen is supporting, sponsoring and promoting evidence-based research to uncover systemic bias, identify unmet patient needs, and propel healthcare systems toward change. Groundbreaking research already underway includes a data-based tool to help health systems identify groups of patients with inadequate PAD care and better direct efforts toward those placed at the highest risk of amputation, as well as a series of white papers that highlight best practices of leading limb salvage programs for people at risk for amputation.
“Everyone deserves a chance to avoid an amputation. I grew up in my dad’s podiatry practice and I saw from a young age what a difference you can make in simply helping people move through the world,” said David G. Armstrong**, Ph.D., D.P.M., Professor of Surgery and Director of the Southwestern Academic Limb Salvage Alliance (SALSA), at Keck School of Medicine, University of Southern California, and President of the American Limb Preservation Society (ALPS). “Limb preservation is of paramount importance, and I believe in the big idea that, together, we can eliminate limb amputations over the next generation. The inspiring thing is that – even with so many factors collectively stacked against our patients, ongoing research, awareness and sharing of best practices is vital to ensure we help people with PAD protect their legs and avoid the devastating consequences of amputation.”
Collaboration to Unlock Better PAD Care and Improve Outcomes
Through Save Legs. Change Lives.™ Janssen is collaborating with powerful partners, including universities, health systems, non-governmental organizations and change makers to break down barriers to equitable and inclusive care, ranging from access and health literacy to health-care provider diversity.
The Company, through Janssen Scientific Affairs, LLC, is proud to help support the American Heart Association’s PAD National Action Plan, which aims to reduce PAD-related amputation. Additionally, Janssen is sponsoring the American College of Cardiology Foundation’s “Change the FIELD” initiative, a major multi-year effort to foster inclusivity, equity, leadership and diversity in the field of cardiology.
About the Janssen Pharmaceutical Companies of Johnson & Johnson
At Janssen, we’re creating a future where disease is a thing of the past. We’re the Pharmaceutical Companies of Johnson & Johnson, working tirelessly to make that future a reality for patients everywhere by fighting sickness with science, improving access with ingenuity, and healing hopelessness with heart. We focus on areas of medicine where we can make the biggest difference: Cardiovascular & Metabolism, Immunology, Infectious Diseases & Vaccines, Neuroscience, Oncology, and Pulmonary Hypertension.